Authors
Bingyang Xu, Hao Chen, Jiali Chu, Yuanqin Wang, Nan Kou, Biao Yu, Tong Xiao, Peiwen Yang, Ying He, Na Wu, Hong Sun, Yumin Xia, Hongying Zhang, Tianxiao Zhang, Jiawen Wu
Published in
Journal of the American Academy of Dermatology. Nov 10, 2026. Epub Nov 10, 2026.
Abstract
Hyperplastic rosacea is difficult to treat. Sirolimus may be a topical option.
To evaluate topical sirolimus gel and explore two-dimensional-to-three-dimensional approximate protrusion volume (APV) assessment.
In this randomized, double-blind, placebo-controlled trial, 65 patients applied 0.2% sirolimus gel (n = 29) or placebo (n = 36) twice daily. The primary endpoint was an Investigator's Global Assessment (IGA) score ≤1 after a 12-week cycle. Secondary and exploratory endpoints included Clinician's Erythema Assessment (CEA) success, artificial intelligence-estimated APV change, subgroup analyses, and correlations between APV and clinical scores.
IGA success was 72.4% versus 33.3% (adjusted relative risk, 1.949; 95% confidence interval [CI], 1.153-3.294; P = .013), and CEA success was 69.0% versus 30.6% (adjusted relative risk, 2.778; 95% CI, 1.627-4.743; P < .001). APV reduction was greater with sirolimus (-61.556 units; P < .001). Baseline APV correlated with IGA (ρ = 0.386; P = .001) and CEA (ρ = 0.314; P = .011). No serious adverse events occurred.
Single-center design, small sample, short follow-up, unvalidated algorithm, and no systemic absorption, quality-of-life, or satisfaction assessments.
Topical sirolimus gel showed exploratory clinical and APV signals; confirmatory trials are needed.
PMID:
43007256
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 23
- Comments 0